Overview

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine clinical practice.
Details
Lead Sponsor:
Bayer
Treatments:
Radium Ra 223 dichloride